Foundational & Translational Research
Leverage our validated research tools and testing expertise to accelerate preclinical studies and drug discovery
GTM Offers Kits and Services to Fit Any RT-PCR, Digital PCR, or Sequencing Application
Our utilization of dPCR technology accurately quantifies your target of interest by using our high-performance reaction conditions for performing PCR in nanodroplets. Sample dilution minimizes PCR inhibition and the need for a standard curve. Target quantification is calculated based on a Poisson distribution of nanodroplet reactions that contain the target sequence. GTM offers high-throughput dPCR oncology panels, customized dPCR assay design, and sample testing in our state-of-the-art facility.
We use NGS technology to accurately sequence DNA in a high-throughput platform. NGS data can be used to assemble shorter sequencing reads into longer reads and determine the number of times a particular sequence is detected in a sample. GTM offers customized NGS services to sequence, detect, or quantify any nucleic acid target.
Our digital RT-PCR and Digital PCR (dPCR) Cancer Research Test Kits include all of the validated primers, probes, and wild-type and mutant controls required for your assay.
GT-Plex™ Multiplexed Digital PCR Kits and Services
Increase throughput
Our multiplexed dPCR kits save you time and money by testing multiple mutations in a single reaction
Multiplex oncology targets
GT-Plex™ multiplex kits are available for EGFR, IDH1/IDH2/NMP1, KRAS and many more mutations
Customize your assay
Our team can design multiplexed assays for your targets of interest
Run in-house or outsource to GTM
Kits are developed and optimized for several Real-Time and digital platforms including; Bio-Rad QX100™, QX200™, QX600™, QIAGEN QIAcuity®, and Roche Digital LightCycler® systems
(PATENTED AND PATENTS-PENDING)
For research use only. Not for use in diagnostic procedures.
GT-Plex™ EGFR Multiplex Digital PCR Assay
Key Advantages:
- Targets over 30 actionable mutations in the EGFR gene spanning exons 18 through 21
- Validated for 11 targets, including 8 TKI-sensitive and 3 TKI-resistant mutations
- Optimized for the Bio-Rad QX100™, QX200™, QX600™, and QIAGEN QIAcuity®
- Demonstrates excellent sensitivity and robust performance over a broad dynamic range
- Eliminates interference from PCR inhibitors compared to RT-qPCR
- Multiplex for faster throughput and lower reagent cost
- Includes all necessary controls
- Compatible with FFPE and cfDNA/ctDNA samples
Key Benefits
Detect as few as 3 copies of target DNA per reaction and genotype samples with low DNA concentrations
Leverage our GT-Plex™ technology to amplify more targets in each assay, saving you time and money
Assay your samples with validated kits that include all necessary primers, probes, and controls
Eliminate interference from PCR inhibitors using dPCR technology
Cancer Gene Targets
BCR-ABL Fusion
Chronic myelogenous leukemia
Quantify fusions between the breakpoint cluster region (BCR) gene and the tyrosine-protein kinase gene ABL1
EGFR
Brain, colorectal, and lung cancers
Assess 11 targets in the epidermal growth factor receptor gene, including 8 TKI-sensitive and 3 TKI-resistant mutations
ESR1
Breast cancer
Detect mutations in the estrogen receptor 1 gene
IDH1 and IDH2
Acute myeloid leukemia
Test for mutations in genes that code for isocitrate dehydrogenase 1 and 2
KRAS
Lung, colorectal, and pancreatic cancers
Test for mutations in genes that code for isocitrate dehydrogenase 1 and 2
NPM1-W288FS*12 Insertion Detection
Acute myeloid leukemia
Identify the most common exon 12 mutation that causes
cytoplasmic sequestration of nucleophosmin 1
New Targets in Development
Suggested Kits
GT Molecular PCR Kit Advantages
FAQs